Dr. Micallef on NuQ Blood Tests in Prostate Cancer

Jake Micallef, PhD
Published: Tuesday, Oct 04, 2016



Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

The test itself only needs a very small volume of blood to be done in a routine health check. Moreover, given its significantly low cost and current availability in most hospitals and doctors' offices, Micallef explains that this test could be rolled out very quickly on a number of platforms.

With the use of circulating tumor DNA, the test looks at the whole structure of chromosome fragments, including the DNA, but not its sequence, explains Micallef. Overall, this tool achieves a higher specificity in cancer detection than prostate-specific antigen screening.
SELECTED
LANGUAGE


Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

The test itself only needs a very small volume of blood to be done in a routine health check. Moreover, given its significantly low cost and current availability in most hospitals and doctors' offices, Micallef explains that this test could be rolled out very quickly on a number of platforms.

With the use of circulating tumor DNA, the test looks at the whole structure of chromosome fragments, including the DNA, but not its sequence, explains Micallef. Overall, this tool achieves a higher specificity in cancer detection than prostate-specific antigen screening.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x